adamantane has been researched along with Bile Duct Cancer in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boakye, J; Chaiteerakij, R; Chen, G; Ding, X; Huang, S; Li, Y; Moser, CD; Ndzengue, A; Roberts, LR; Shaleh, H; Sinicrope, FA; Smith, CD; Thomas, MB; Zhou, Y; Zou, X | 1 |
1 other study(ies) available for adamantane and Bile Duct Cancer
Article | Year |
---|---|
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Topics: Adamantane; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Drug Synergism; Drug Therapy, Combination; Humans; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Cells, Cultured | 2016 |